Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus PEG 3350 SODIUM CHLORIDE SODIUM BICARBONATE POTASSIUM CHLORIDE AND BISACODYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus PEG 3350 SODIUM CHLORIDE SODIUM BICARBONATE POTASSIUM CHLORIDE AND BISACODYL.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Combination of osmotic laxative (PEG-3350, sodium chloride, sodium bicarbonate, potassium chloride) and stimulant laxative (bisacodyl). PEG-3350 causes water retention in colon, increasing stool water content and volume, stimulating peristalsis. Electrolytes maintain fluid/electrolyte balance. Bisacodyl stimulates colonic smooth muscle contraction and inhibits water absorption.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
For colonoscopy preparation: Day 1: 4 bisacodyl tablets (5 mg each) orally at 2000. Day 2: 1 liter of PEG-3350 plus electrolytes solution (4 sachets dissolved in 4 liters water) orally at 0800; then 2 liters more over 3-4 hours. Alternatively, split-dose regimen: 2 liters evening before colonoscopy and 2 liters morning of procedure.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
PEG-3350: not applicable (non-absorbed). Bisacodyl: terminal half-life 8–16 hours; clinical effect peaks within 6–12 hours.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
PEG-3350 is not absorbed, excreted unchanged in feces. Electrolytes (sodium chloride, sodium bicarbonate, potassium chloride) are absorbed and renally excreted; bisacodyl is primarily excreted as glucuronide conjugates in feces (biliary) and urine (renal). Approximately 95% of bisacodyl is recovered in feces, 5% in urine.
Category C
Category A/B
Electrolyte
Electrolyte